PGYM

Genetic evaluation of AMPD1, CPT2, and PGYM metabolic enzymes in patients with chronic fatigue syndrome

P. E. Maltese, Venturini, L., Poplavskaya, E., Bertelli, M., Cecchin, S., Granato, M., Nikulina, S. Y., Salmina, A., Aksyutina, N., Capelli, E., Ricevuti, G., Lorusso, L., Maltese, P. E., Venturini, L., Poplavskaya, E., Bertelli, M., Cecchin, S., Granato, M., Nikulina, S. Y., Salmina, A., Aksyutina, N., Capelli, E., Ricevuti, G., and Lorusso, L., Genetic evaluation of AMPD1, CPT2, and PGYM metabolic enzymes in patients with chronic fatigue syndrome, vol. 15, p. -, 2016.

Chronic fatigue syndrome (CFS) is a disease that can seriously impair one’s quality of life; patients complain of excessive fatigue and myalgia following physical exertion. This disease may be associated with abnormalities in genes affecting exercise tolerance and physical performance. Adenosine monophosphate deaminase (AMPD1), carnitine palmitoyltransferase II (CPT2), and the muscle isoform of glycogen phosphorylase (PYGM) genes provide instructions for producing enzymes that play major roles in energy production during work.

Subscribe to PGYM